Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/neu in Patients with Breast Cancer

被引：0
|
作者：
Susanne Taucher
Margaretha Rudas
Robert M. Mader
Michael Gnant
Emanuel Sporn
Peter Dubsky
Sebastian Roka
Thomas Bachleitner
Florian Fitzal
Daniela Kandioler
Catharina Wenzel
Günther G. Steger
Martina Mittlböck
Raimund Jakesz
机构：
[1] Vienna University Medical School,Department of Surgery
[2] Vienna University Medical School,Department of Pathology
[3] Vienna University Medical School,undefined
来源：
Breast Cancer Research and Treatment | 2003年 / 82卷
关键词：
breast cancer; core needle biopsy; docetaxel; epirubicin; FISH; HER2/; immunohistochemistry; preoperative treatment; trastuzumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background. In primary breast cancer, the expression levels of biological markers relevant to the progression of the disease may be altered by administration of anticancer drugs. Since neoadjuvant chemotherapy with epirubicin and docetaxel is increasingly used in advanced breast cancer, our purpose was to assess the influence of this neoadjuvant chemotherapy on the expression of the growth factor receptor HER2/neu.
引用
收藏
页码：207 / 213
页数：6
相关论文
共 50 条
  • [1] Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer
    Taucher, S
    Rudas, M
    Mader, RM
    Gnant, M
    Sporn, E
    Dubsky, P
    Roka, S
    Bachleitner, T
    Fitzal, F
    Kandioler, D
    Wenzel, C
    Steger, GG
    Mittlböck, M
    Jakesz, R
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 (03) : 207 - 213
  • [2] Influence of Neoadjuvant Chemotherapy on HER2/neu Status in Invasive Breast Cancer
    Li, Peifeng
    Liu, Tantan
    Wang, Yingmei
    Shao, Shuai
    Zhang, Weichen
    Lv, Yang
    Yi, Jun
    Wang, Zhe
    CLINICAL BREAST CANCER, 2013, 13 (01) : 53 - 60
  • [3] HER2 overexpression predicts survival in stage II and III of breast cancer patients treated with neoadjuvant docetaxel plus epirubicin
    不详
    VIRCHOWS ARCHIV, 2005, 447 (02) : 364 - 365
  • [4] Serum HER2/neu levels in breast cancer patients with different level of tumor HER2/neu protein expression
    Kushlinsky, Nicolai
    Gershtein, Elena
    Shyroky, Vyacheslav
    Ermilova, Valeriya
    Tchemeris, Galina
    Letyagin, Victor
    TUMOR BIOLOGY, 2007, 28 : 95 - 95
  • [5] The influence of hormone receptor status and HER1 and HER2 expression on the response to neoadjuvant therapy in breast cancer patients
    Bonigliere, L.
    Torrisi, R.
    Pruneri, G.
    Colleoni, M.
    Viale, G.
    LABORATORY INVESTIGATION, 2008, 88 : 24A - 24A
  • [6] The influence of hormone receptor status and HER1 and HER2 expression on the response to neoadjuvant therapy in breast cancer patients
    Bouiglieri, L.
    Torrisi, R.
    Pruneri, G.
    Colleoni, M.
    Viale, G.
    MODERN PATHOLOGY, 2008, 21 : 24A - 24A
  • [7] Loss of HER2 expression in HER2-positive breast cancer patients after neoadjuvant therapy
    Sang, Yuting
    Wu, Jiong
    Yang, Benlong
    CANCER RESEARCH, 2022, 82 (04)
  • [8] HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in operable breast cancer.
    Learn, PA
    Yeh, IT
    McNutt, M
    Chisholm, GB
    Pollock, BH
    Rousseau, DL
    Sharkey, FE
    Cruz, AB
    Kahlenberg, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 853S - 853S
  • [9] HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma
    Learn, PA
    Yeh, IT
    McNutt, M
    Chisholm, GB
    Pollock, BH
    Rousseau, DL
    Sharkey, FE
    Cruz, AB
    Kahlenberg, MS
    CANCER, 2005, 103 (11) : 2252 - 2260
  • [10] HER2/neu expression in Venezuelan patients with locally advanced breast cancer
    Morales, Luisa
    Reigosa, Aldo
    Caleiras, Eduardo
    Mora, Richard
    Marrero, Nuria
    Payares, Eliecer
    Molina, Karla
    Sucre, Luis
    INVESTIGACION CLINICA, 2008, 49 (01): : 69 - 78
12345